,,iii  #aae? ,,congress  #b;d ,session  
,s4 ,,res4 #dcg  ,,9 ,,! ,,s5ate ,,( ,,!
 ,,unit$ ,,/ates  ,m>* #ai1 #bjah,mr4   
,br[n 7= himself & ,mr4 ,sullivan7      
submitt$ ! foll[+ resolution2 :i* 0     
ref]r$ to ! ,committee on ,=eign        
,relations  ,,resolution  ,support+ !   
goals ( ,_w ,tub]culosis ,day to raise  
aw>5ess ab\t tub]culosis4  ,:]eas  ( !  
population ( ! _w is infect$ ) !        
tub]culosis bact]ium 7commonly ref]r$ to
 z ,,tb72 ,:]eas ! ,_w ,heal?           
,organization 7commonly ref]r$ to z !   
,,:o7 e/imates t #aj1djj1jjj p 7 newly  
infect$ ) ,,tb 9 #bjaf1 #aj p]c5t ( :om 
7 also infect$ ) ! human immunodefici5cy
 virus 7commonly ref]r$ to z ,,hiv72    
,:]eas1 9 #bjaf1 ,,tb kill$ an e/imat$  
#a1gjj1jjj p1 caus+ m dea?s worldwide   
?an any o!r s+le infecti\s ag5t2 ,:]eas 
m ?an #hj p]c5t ( ,,tb dea?s among      
,,hiv-negative p 9 #bjaf occurr$ 9      
,africa & ,s\!a/ ,asia1 & ,india acc\nt$
 = #cc p]c5t ( global ,,hiv-negative    
,,tb dea?s2 ,:]eas ,,tb is a lead+ kill]

 ( p infect$ ) ,,hiv1 & #djj1jjj p )    
,,hiv di$ ( ,,tb 9 #bjaf2 ,:]eas        
additional vuln]able populations at high
 risk = develop+ ,,tb include pregnant  
wom5 & newborns2 ,:]eas ,,tb is #a ( !  
#e lead+ causes ( dea? among adult wom5 
betwe5 ! ages ( #bj & #ei 9 l[-income   
c\ntries1 & wom5 ) ,,tb c face /igma1   
discrim9ation1 & 9 "s sett+s            
o/racization by _! families &           
communities2 ,:]eas ! global ,,tb       
epidemic & ! spread ( drug-resi/ant ,,tb
 pres5t a p]si/5t public heal? ?reat to 
! ,unit$ ,/ates because ! disease does n
 recognize bord]s2 ,:]eas               
antibiotic-resi/ant pa?og5s are a gr[+  
problem worldwide1 & drug-resi/ant ,,tb 
c occur :5 ! drugs us$ to treat ,,tb are
 misus$ or mismanag$2 ,:]eas /udies h   
demon/rat$ direct p]son-to-p]son        
transmission ( drug-resi/ant ,,tb2      
,:]eas multi-drug resi/ant ,,tb         
7commonly ref]r$ to z 8,,mdr-,,tb07 is  
caus$ by bact]ia ) resi/ance to rifamp9 
& isoniazid1 ! #b mo/ pot5t treatm5ts = 

,,tb infection2 ,:]eas1 accord+ to !    
#bjag ,,:o ,global ,tub]culosis ,report1
 9 #bjaf an e/imat$ #d4a p]c5t ( all new
 ,,tb cases & #ai p]c5t ( previ\sly     
treat$ cases 7 ,,mdr-,,tb or            
rifamp9-resi/ant ,,tb2 ,:]eas1 9 #bjaf1 
an e/imat$ #fjj1jjj p ar\nd ! _w        
develop$ ,,mdr-,,tb or rifamp9-resi/ant 
,,tb & ^? drug-resi/ant /ra9s caus$     
approximately #bdj1jjj dea?s worldwide2 
,:]eas ext5sively drug-resi/ant ,,tb    
7commonly ref]r$ to z 8,,xdr-,,tb07 is a
 r>e type ( ,,tb t is resi/ant to ne>ly 
all m$ic9es1 & !re=e c be v difficult & 
exp5sive to treat1 especially among     
pati5ts ) ,,hiv & acquir$ immune        
defici5cy syndrome 7commonly ref]r$ to z
 ,,aids72 ,:]eas1 accord+ to ! #bjag    
,,:o ,global ,tub]culosis ,report1 9    
#bjae1 #abc c\ntries report$ at lea/ #a 
case ( ,,xdr-,,tb2 ,:]eas1 9 #bjaf1 !   
,c5t]s = ,disease ,control & ,prev5tion 
e/imat$ t ! co/ ( treat+ a s+le pati5t )
 ,,mdr-,,tb 9 ! ,unit$ ,/ates av]ag$    
#afj1jjj1 & ! av]age co/ ( treat+ a     

pati5t ) ,,xdr-,,tb 0 ev5 high] at      
#eac1jjj1 comp>$ ) #ah1jjj to treat a   
pati5t ) drug-susceptible ,,tb2 ,:]eas  
,,mdr-,,tb & ,,xdr-,,tb cases 9 ! ,unit$
 ,/ates betwe5 #bjje & #bjjg            
collectively co/ ! heal? c>e sy/em an   
e/imat$ #ec1jjj1jjj1 accord+ to an      
analysis by ! ,c5t]s = ,disease ,control
 & ,prev5tion2 ,:]eas1 9 a #bjjj report1
 ! ,in/itute ( ,m$ic9e f\nd t a decrease
 9 ,,tb control fund+ & ! spread ( ,,hiv
 & ,,aids caus$ a resurg5ce ( ,,tb 9 !  
late #aihjs & e>ly #aiijs2 ,:]eas a     
total ( #i1bgb ,,tb cases 7 report$ 9 ! 
,unit$ ,/ates 9 #bjaf1 repres5t+ all #ej
 ,/ates & ! ,di/rict ( ,columbia1 & up  
to #ac1jjj1jjj p 9 ! ,unit$ ,/ates may  
be liv+ ) lat5t ,,tb infection2 ,:]eas  
#ge p]c5t ( ,/ates h report$ an increase
 9 ! proportion ( complex cases ( ,,tb 9
 rec5t ye>s due to factors su* z        
homelessness1 ,,hiv infection1 drug     
resi/ance1 sub/ance abuse1 refugee      
/atus1 & o!r factors2 ,:]eas ! rate (   
,,tb disease 9 ,african ,am]icans is #h 

times high] ?an ! rate 9 ,:ite          
non-,hispanic ,am]icans1 & significant  
disp>ities exi/ among o!r m9orities 9 ! 
,unit$ ,/ates1 includ+ ,native ,am]icans
 & ,alaska ,natives1 ,asian ,am]icans1 &
 ,hispanic ,am]icans1 ) #hf p]c5t ( all 
report$ ,,tb cases 9 ! ,unit$ ,/ates 9  
#bjaf occurr+ 9 racial or e?nic         
m9orities2 ,:]eas1 globally 9 #bjaf1 an 
e/imat$ #a1jjj1jjj *ildr5 develop$ ,,tb 
& #bej1jjj *ildr5 di$ ( ,,tb2 ,:]eas    
smok+ greatly increases ! risk ( dea? f 
,,tb1 & m ?an #bj p]c5t ( ,,tb cases    
worldwide may be attributable to smok+2 
,:]eas diabetes is a major risk factor =
 ,,tb1 & p ) diabetes are m likely to   
develop ,,tb & h a high] risk ( dea? due
 to ,,tb2 ,:]eas b$aquil9e is an        
antibiotic t boo/s an ,,mdr-,,tb        
pati5t's *ance ( survival f             
approximately #ej p]c5t to z mu* z #hj  
p]c5t1 & ?r\gh a public-private         
p>tn]%ip1 ! ,unit$ ,/ates ,ag5cy =      
,int]national ,developm5t 7commonly     
ref]r$ to z ,,usaid7 assi/s m ?an #h1jjj

 pati5ts 9 almo/ #dj c\ntries 9 access+ 
?is new m$ication2 ,:]eas ,bacillus     
,calmette-,gu]91 a ,,tb vacc9e t is kn[n
 z ,,bcg1 provides "s protection to     
*ildr5 b has _h little epidemiologic    
impact on ,,tb worldwide2 ,:]eas !re is 
a critical ne$ = new drugs1 diagno/ics1 
& vacc9es = controll+ ! global ,,tb     
epidemic2 ,:]eas ! ,,:o has call$ =     
8global solid>ity & action0 to support a
 #bj-ye> /rategy to end ! global ,,tb   
epidemic2 ,:]eas ! enactm5t ( ! ,tom    
,lantos & ,h5ry ,j4 ,hyde ,unit$ ,/ates 
,global ,lead]%ip ,aga9/ ,,hiv_/,,aids1 
,tub]culosis1 & ,mal>ia ,reau?orization 
,act ( #bjjh 7,public ,law #aaj-bic2    
#abb ,/at4 #biah71 & ! ,compreh5sive    
,tub]culosis ,elim9ation ,act ( #bjjh   
7,public ,law #aaj-cib2 #abb ,/at4      
#daie7 provid$ a hi/oric ,unit$ ,/ates  
commitm5t to ! global eradication (     
,,tb1 includ+ a commitm5t to treat      
#d1ejj1jjj ,,tb pati5ts & #ij1jjj       
,,mdr-,,tb pati5ts betwe5 #bjji & #bjac 
& to provide additional treatm5t ?r\gh  

coord9at$ multilat]al ef=ts2 ,:]eas     
,,usaid provides f9ancial & te*nical    
assi/ance to #bc c\ntries highly burd5$ 
by ,,tb1 helps to support ! developm5t (
 new diagno/ic & treatm5t tools1 & is   
au?oriz$ to support rese>* to develop   
new vacc9es to combat ,,tb2 ,:]eas ,,tb 
incid5ce 9 ! c\ntries t receive bilat]al
 ,,tb fund+ f ! ,unit$ ,/ates ?r\gh     
,,usaid has decreas$ by ne>ly #a_/e s9ce
 #bjjj2 ,:]eas ! ,c5t]s = ,disease      
,control & ,prev5tion1 p>tn]+ ) o!r     
entities ( ! ,unit$ ,/ates & individual 
,/ates & t]ritories1 directs ! national 
,,tb elim9ation program1 coord9ates ,,tb
 surveillance1 te*nical assi/ance1 &    
prev5tion activities1 & helps to support
 ! developm5t ( new diagno/ic1 treatm5t1
 & prev5tion tools to combat ,,tb2      
,:]eas ! ,national ,in/itutes ( ,heal?1 
?r\gh its _m in/itutes & c5t]s1 plays ! 
lead+ role 9 basic & cl9ical rese>* on !
 id5tification1 treatm5t1 & prev5tion ( 
,,tb2 ,:]eas ! ,global ,fund to ,fight  
,,aids1 ,tub]culosis1 & ,mal>ia         

7commonly ref]r$ to z ! ,global ,fund71 
to :i* ! ,unit$ ,/ates is a top f9ancial
 donor1 provides m ?an #fe p]c5t ( all  
int]national f9anc+ = ,,tb programs2    
,:]eas1 to date1 ,global ,fund-support$ 
programs h detect$ & treat$ #ag1djj1jjj 
cases ( ,,tb2 & ,:]eas ,m>* #bd1 #bjah1 
is ,_w ,tub]culosis ,day1 a day t       
commemorates ! date 9 #ahhb on :i* ,dr4 
,rob]t ,ko* ann\nc$ 8 discov]y (        
,mycobact]ium tub]culosis1 ! bact]ia t  
causes ,,tb3 ,n[1 !re=e1 be x  ,t !     
,s5ate-- 7#a7 supports ! goals ( ,_w    
,tub]culosis ,day to raise aw>5ess ab\t 
tub]culosis2  7#b7 comm5ds ! progress ( 
tub]culosis bact]ia elim9ation ef=ts by 
entities t include ! ,int]ag5cy ,work+  
,gr\p on ,u4,s4 ,gov]nm5t-,sponsor$     
,int]national ,ex*anges & ,tra9+1 !     
,unit$ ,/ates ,ag5cy = ,int]national    
,developm5t1 ! ,c5t]s = ,disease        
,control & ,prev5tion1 ! ,national      
,in/itutes ( ,heal?1 ! ,_w ,heal?       
,organization1 & ! ,global ,fund to     
,fight ,,aids1 ,tub]culosis1 & ,mal>ia2 

&  7#c7 reaffirms ! commitm5t to /r5g!n 
! ,unit$ ,/ates lead]%ip & effectiv5ess 
( ! global response to tub]culosis4